A phase II study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients with progressive, metastatic, castration-resistant prostate cancer
| Autor: | Alonso-Gordoa, T., Goodman, M., Vulsteke, C., Roubaud, G., Zhang, J., Parikh, M., Piulats, J.M., Azaro, A., James, G.D., Cavazzina, R., Gangl, E.T., Thompson, J., Pouliot, G., Kumar, R., Sweeney, C. |
|---|---|
| Zdroj: | In ESMO Open June 2024 9(6) |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|